Follow-up data show MAL-PDT treatment effective: MAL-PDT equals other treatments' efficacy, topping them in cosmetic outcome and patient preference.(Clinical Rounds)

Publication: Skin & Allergy News

Publication Date: 01-JUL-05

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2005 International Medical News Group

VIENNA -- Topical methyl aminolevulinate in combination with photodynamic therapy should be considered one of the standard therapies for basal cell carcinoma, Colin A. Morton, M.D., reported at the 10th World Congress on Cancers of the Skin.

MAL-PDT was approved in the United States in 2004 for the treatment of actinic keratoses (AKs), and is already approved for the treatment of AKs and/or basal cell carcinoma (BCC) in most European countries, New...

Read the full article for free courtesy of your local library.